Biogen CEO Plots A Slow Return To Growth As Revenue Set To Shrink Again In 2023
Cost Cuts, R&D Prioritization, Deals All On The Table
Christopher Viehbacher told his first earnings call as CEO that a review is under way to reverse Biogen’s fortunes, but noted Leqembi will not be a meaningful contributor while treatment and reimbursement bottlenecks remain.
